As of June 21, 2025, Invictus MD Strategies Corp (GENE.H.V) reports a Gross Margin of 28.41%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Invictus MD Strategies Corp's Gross Margin
Over recent years, Invictus MD Strategies Corp's Gross Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2019-01-31 | 28.41% |
| 2018-01-31 | 14.64% |
| 2017-01-31 | 38.81% |
| 2016-01-31 | 35.27% |
This slight upward trend highlights how Invictus MD Strategies Corp manages its operational efficiency and pricing power over time.
Comparing Invictus MD Strategies Corp's Gross Margin to Peers
To better understand Invictus MD Strategies Corp's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Invictus MD Strategies Corp (GENE.H.V) | 28.41% |
| NanoSphere Health Sciences Inc (NSHS.CN) | 7775.20% |
| Rise Life Science Corp (RLSC.CN) | 6291.29% |
| Tree of Knowledge International Corp (TOKI.CN) | 2992.87% |
| Intellipharmaceutics International Inc (IPCI.TO) | 100.00% |
| Provention Bio Inc (PRVB) | 96.03% |
Compared to its competitors, Invictus MD Strategies Corp's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.